12:16 PM J&J (JNJ +0.4%) is seeking accelerated FDA approval for bedaquiline, the first new type of drug to treat tuberculosis in over four decades, and the first for specifically fighting the increasingly common strain of the disease that is resistant to multiple drugs. J&J filing is supported by data from a Phase II trial. (PR) (Read the comments on this)
See more Market Currents on Healthcare
Why are you receiving this? You subscribed to real-time Market Currents alerts at Seeking Alpha.
If this email was forwarded to you and you wish to subscribe to this email, click here.
Manage your emails:
I'm no longer following JNJ: unsubscribe from all JNJ email alerts
This type of alert isn't helpful to me: unsubscribe from Market Currents (breaking news) alerts on JNJ
I'm getting too many emails: manage your email alert choices
Get alerts on additional tickers and manage all your email alert choices here
To ensure you receive these emails in the future, please add account@seekingalpha.com to your address book, contacts or list of safe senders.
Sent by Seeking Alpha, 345 7th Ave. Suite 1400 New York, NY 10001
